| SC 13G/A | 2022-02-10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Syndax Pharmaceuticals Inc | 1,200,000 | 2.3% | EDGAR |
| SC 13G/A | 2022-02-07 | BlackRock Inc. | Syndax Pharmaceuticals Inc | 3,689,894 | 7.0% | EDGAR |
| SC 13G/A | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Syndax Pharmaceuticals Inc | 1,598,766 | 3.0% | EDGAR |
| SC 13G | 2021-12-23 | Frazier Life Sciences Public Fund, L.P. | Syndax Pharmaceuticals Inc | 1,583,927 | 3.2% | EDGAR |
| SC 13G | 2021-05-10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Syndax Pharmaceuticals Inc | 2,700,000 | 5.6% | EDGAR |
| SC 13D | 2021-05-03 | Access Industries Holdings LLC | Syndax Pharmaceuticals Inc | 2,682,387 | - | EDGAR |
| SC 13G/A | 2021-04-20 | Avidity Partners Management LP | Syndax Pharmaceuticals Inc | 4,750,000 | 9.9% | EDGAR |
| SC 13G/A | 2021-02-16 | Avidity Partners Management LP | Syndax Pharmaceuticals Inc | 3,308,000 | 7.1% | EDGAR |
| SC 13G/A | 2021-02-16 | Boxer Capital, LLC | Syndax Pharmaceuticals Inc | 2,358,005 | 5.0% | EDGAR |
| SC 13G/A | 2021-02-12 | BIOTECHNOLOGY VALUE FUND L P | Syndax Pharmaceuticals Inc | 1,962,220 | 4.0% | EDGAR |
| SC 13G/A | 2021-02-12 | MPM BioVentures IV QP LP | Syndax Pharmaceuticals Inc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2021-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Syndax Pharmaceuticals Inc | 2,615,443 | 5.5% | EDGAR |
| SC 13G/A | 2021-02-04 | Access Industries Holdings LLC | Syndax Pharmaceuticals Inc | 2,138,200 | 4.6% | EDGAR |
| SC 13G | 2021-02-02 | BlackRock Inc. | Syndax Pharmaceuticals Inc | 2,320,406 | 5.0% | EDGAR |
| SC 13G/A | 2021-01-21 | Domain Partners VIII, L.P. | Syndax Pharmaceuticals Inc | 737,239 | 1.6% | EDGAR |
| SC 13G/A | 2020-12-10 | WELLINGTON MANAGEMENT GROUP LLP | Syndax Pharmaceuticals Inc | 2,174,223 | 5.3% | EDGAR |
| SC 13G | 2020-11-04 | Avidity Partners Management LP | Syndax Pharmaceuticals Inc | 2,600,000 | 6.7% | EDGAR |
| SC 13G/A | 2020-09-09 | BlackRock Inc. | Syndax Pharmaceuticals Inc | 1,827,426 | 4.7% | EDGAR |
| SC 13G | 2020-05-11 | Boxer Capital, LLC | Syndax Pharmaceuticals Inc | 2,763,569 | 7.6% | EDGAR |
| SC 13G/A | 2020-02-14 | BIOTECHNOLOGY VALUE FUND L P | Syndax Pharmaceuticals Inc | 1,899,545 | 6.7% | EDGAR |